---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-015648"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:30:21.339485+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology terminates CCO Jeff J. Ludwig; no replacement named

## Summary
- Terminated Jeff J. Ludwig as Chief Commercial Officer and employee on May 8, 2025.
- Mr. Ludwig may receive severance per his employment offer letter contingent on signing a release within 60 days.
- Company will not appoint a new CCO; responsibilities absorbed by existing sales and marketing personnel.

## SEC filing metadata
- accession: 0001437749-25-015648
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774925015648/0001437749-25-015648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774925015648/pbyi20250507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-015648
- JSON: https://secwatch.observer/filing/0001437749-25-015648.json
- Plain text: https://secwatch.observer/filing/0001437749-25-015648.txt

## Key facts
- Executive change
  Jeff J. Ludwig was terminated as Chief Commercial Officer at PUMA BIOTECHNOLOGY, INC..
  - Action: terminated
  - Role: Chief Commercial Officer
  source text: On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774925015648/0001437749-25-015648-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.